NSE: SHALBY | BSE: 540797

Expensive Rocket

Download real time

240.57 5.25 (2.23%)

35.72% Gain from 52W Low

776.5K NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

2,598.4

Market Cap

Above industry Median

1.2

Beta 1Year

High Volatility

Shalby Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SHALBY, BSE:540797 Shalby Ltd.

Shalby Ltd.

29 Jul 2022

240.57

2.23%

Shalby Ltd

Buy: Shalby Ltd.

Target

ICICI Direct

Shalby Ltd. is trading above all available SMAs

Shalby Ltd.

03 Jun 2022

240.57

2.23%

Shalby Ltd

Buy: Shalby Ltd.

ICICI Direct

Shalby Ltd. has gained 32.60% in the last 3 Months

Shalby Ltd.

07 Feb 2022

240.57

2.23%

Shalby Ltd

Buy: Shalby Ltd.

Recommendation

ICICI Securities Limited

Therapy-wise breakup Q3FY22: anthroplasty:38%, critical care & general medicine: 11%, orthopaedic: 9%, oncology:10%, cardiac science:10%, neurology 6%, nephrology:3%, others:13% Shalby registered a blended ARPOB of | 32,049 and ALOS of 4.02 days (without day care procedures) in Q3FY22 Acquisition of US based Consensus to diversify into related implant...

Shalby Ltd. is trading above all available SMAs

Shalby Ltd.

08 Nov 2021

240.57

2.23%

Shalby Ltd | Growth Ready!

Buy: Shalby Ltd.

Target

Monarch Networth Capital Limited

Shalby Ltd (Shalby') came out with its Q2FY22 results which reported sequential margin degrowth on the back of implants businesses losses and reduced covid related tailwinds (16.2% vs 25.5% for Q2FY21 vs 20% for Q1FY22). Implant business reported USD 1mn revenue in Q2FY22, guidance for FY22E and FY23E at INR 50crs and INR 100crs respectively. First Ortho Franchise started in Udaipur, expected to open 50 franchises across India over medium term. The newer hospitals (892 beds) reported ~12% EBITDA margins with 37% revenue contribution while mature hospitals (228 beds) reported ~37% EBITDA margins with 29% revenue contribution. Ramp-up of occupancy in newer hospitals will improve the overall EBITDA margin profile. Key optionalities including the Implants business and the franchisee business are yet to play out. We retain a BUY on Shalby with a target price of Rs280, which is 81% upside on CMP. At...

Shalby Ltd. is trading above all available SMAs

Shalby Ltd.

01 Nov 2021

240.57

2.23%

Shalby Ltd

Hold: Shalby Ltd.

Target

ICICI Securities Limited

Shalby is a market leader in arthroplasty procedure (source: F&S Report). It has ~15% market share of all joint replacement surgeries conducted by organised private corporate hospitals in India Ongoing diversification of arthroplasty and orthopaedics with cardiac...

Shalby Ltd. has an average target of 310.00 from 1 broker.

Shalby Ltd.

13 Aug 2021

240.57

2.23%

Shalby Ltd

Hold: Shalby Ltd.

Target

ICICI Securities Limited

...

Shalby Ltd. has gained 19.60% in the last 1 Month

Shalby Ltd.

02 Aug 2021

240.57

2.23%

Shalby Hospitals - Growth Ready

Buy: Shalby Ltd.

Monarch Networth Capital Limited

Shalby Ltd (Shalby') leader in Arthroplasty in India (market share of 15%), remains an under researched and under owned Investment Idea. Its best in class EBITDA margins even with lower occupancy and lower Capex/bed is a testimony of its cost and capital efficient operations. It remains almost net debt free even with the recent increase in its bed capacity by more than 55% and an implant facility acquisition. The newer hospitals (33% of operating beds) to lead EBITDA expansion on account of increased occupancies and asset maturity. Recent Implant facility acquisition provides massive synergies to Shalby with estimated annual savings of INR >11cr. Strong management bench-strength can help turnaround the International Implant business. We thus Initiate Coverage on Shalby with a BUY rating and a target price of INR 320, 29x P/E FY23 earnings, which is an upside of 65% on CMP....

Shalby Ltd. is trading above all available SMAs

Shalby Ltd.

12 Jan 2021

240.57

2.23%

Shalby Ltd

Hold: Shalby Ltd.

Target

ICICI Securities Limited

Rapid ageing, greater life expectancy, lack of exercise and altered lifestyles are driving incidences of osteoarthritis among Indians. Knee replacement surgery in India has been growing in double digits over the years. It is expected to emerge as fourth most common cause of physical disability in India in the next decade. Shalby is a market leader in procedure of arthroplasty (source: F&S; Report). It has ~15% market share of all joint replacement surgeries conducted by organised private corporate hospitals in India. It has performed more than one lakh joint replacements till date....

Shalby Ltd. has gained 32.60% in the last 3 Months

Shalby Ltd.

10 Dec 2019

240.57

2.23%

Shalby Ltd

Hold: Shalby Ltd.

ICICI Securities Limited

The company has a strong brand equity mainly in Gujarat. Shalby has witnessed significant growth in volumes across its hospital network. Arthroplasty continues to dominate its revenue pie although it has been witnessing greater traction in other specialities as well. Leverage free balance sheet, strong margins and continuous generation of free cash flows also provide additional cushion in a capex heavy industry. However, margins are still skewed towered the top two hospitals. We initiate Shalby with HOLD recommendation mainly due to high concentration risk. We value...

Shalby Ltd. is trading above all available SMAs

Shalby Ltd.

05 Dec 2017

240.57

2.23%

Shalby Ltd.

Neutral: Shalby Ltd.

Ashika Research

60 Equity Shares and in multiples thereof. Public issue of 20,354,839 Equity shares of Face value Rs. RII 10 each, (Comprising of fresh issue of 19,354,839 Equity Total Public...

Shalby Ltd. has gained 19.60% in the last 1 Month

Is Shalby Ltd. worth buying?

121 Votes:

Buy 67.77%

Sell 22.31%

Hold 9.92%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf